MONNA

Key Product Details

Product Description

MONNA is a potent TMEM16A (Anoctamin-1) blocker (IC₅₀ = 80 nM). Exhibits >100-fold selectivity for TMEM16A over bestrophin-1, CLC2 and CFTR. Induces vasorelaxation of rodent resistance arteries in presence or absence of chloride ions. Carbachol (Cat. No. 2810) induced contraction of bronchial myocytes is reduced by MONNA and intracellular calcium release is increased.

Product Specifications for MONNA

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for MONNA

The following data is based on the product molecular weight 338.31.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.96 mL	14.78 mL	29.56 mL
5 mM	0.59 mL	2.96 mL	5.91 mL
10 mM	0.30 mL	1.48 mL	2.96 mL
50 mM	0.06 mL	0.30 mL	0.59 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 12 publications citing the usage of this product.

• Boedtkjer New selective inhibitors of calcium-activated chloride channels - T16A(inh) -A01, CaCC(inh) -A01 and MONNA - what do they inhibit? Br.J.Pharmacol. 2015 PMID: 26013995
• Dwivedi The TMEM16A blockers benzbromarone and MONNA cause intracellular Ca²⁺-release in mouse bronchial smooth muscle cells. Eur.J.Pharmacol. 2023 PMID: 36967079
• Oh MONNA, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1. Mol.Pharmacol. 2013 PMID: 23997117

Product Documents for MONNA